335 related articles for article (PubMed ID: 28430376)
41. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
[No Abstract] [Full Text] [Related]
42. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.
Lasocki A; Smith K
J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645
[TBL] [Abstract][Full Text] [Related]
43. Nivolumab-associated bullous pemphigoid reactions involving multiple epitopes.
Aoki Y; Miyagawa F; Miyashita K; Nishimura Y; Hashimoto T; Asada H
Eur J Dermatol; 2019 Oct; 29(5):552-554. PubMed ID: 31570326
[No Abstract] [Full Text] [Related]
44. A Case of Acute Exacerbation of Chronic Adrenal Insufficiency Due to Ipilimumab Treatment for Advanced Melanoma.
Sakaguchi C; Yano S; Ashida K; Wada N; Ohe K; Nagata H; Matsuda Y; Sakamoto S; Sakamoto R; Ohnaka K; Uchi H; Furue M; Nomura M; Ogawa Y
Am J Case Rep; 2019 Jan; 20():106-110. PubMed ID: 30679413
[TBL] [Abstract][Full Text] [Related]
45. Enteritis with immune checkpoint inhibitor use.
Sanders D; Webber D; Chatur N
CMAJ; 2019 Oct; 191(40):E1106. PubMed ID: 31591098
[No Abstract] [Full Text] [Related]
46. Dual checkpoint inhibitor-associated eosinophilic enteritis.
Yang J; Lagana SM; Saenger YM; Carvajal RD
J Immunother Cancer; 2019 Nov; 7(1):310. PubMed ID: 31730503
[TBL] [Abstract][Full Text] [Related]
47. Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia.
Reynolds KL; Sullivan RJ; Fintelmann FJ; Mansour MK; England J
N Engl J Med; 2020 Mar; 382(12):1150-1159. PubMed ID: 32187473
[No Abstract] [Full Text] [Related]
48. Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient.
Fujimura T; Kambayashi Y; Furudate S; Kakizaki A; Hidaka T; Haga T; Hashimoto A; Morimoto R; Aiba S
J Dermatol; 2017 Mar; 44(3):e13-e14. PubMed ID: 27440178
[No Abstract] [Full Text] [Related]
49. Acute cerebellitis after administration of nivolumab and ipilimumab for small cell lung cancer.
Naito T; Osaki M; Ubano M; Kanzaki M; Uesaka Y
Neurol Sci; 2018 Oct; 39(10):1791-1793. PubMed ID: 29948463
[No Abstract] [Full Text] [Related]
50. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
[TBL] [Abstract][Full Text] [Related]
51. Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma.
Cho M; Nonomura Y; Kaku Y; Nakabo S; Endo Y; Otsuka A; Kabashima K
J Dermatol; 2019 Jan; 46(1):e43-e44. PubMed ID: 29863795
[No Abstract] [Full Text] [Related]
52. Dose-dependent toxicity of ipilimumab in metastatic melanoma.
Olischewsky A; De Schrijver S; Bankfalvi A; Wetter A; Zimmer L; Livingstone E; Schadendorf D; Ugurel S
Eur J Cancer; 2018 May; 95():104-108. PubMed ID: 29477367
[No Abstract] [Full Text] [Related]
53. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
[TBL] [Abstract][Full Text] [Related]
54. Combination Nivolumab/Ipilimumab Immunotherapy For Melanoma With Subsequent Unexpected Cardiac Arrest: A Case Report and Review of Literature.
Khoury ZH; Hausner PF; Idzik-Starr CL; Frykenberg MRA; Brooks JK; Dyalram D; Basile JR; Younis RH
J Immunother; 2019 Oct; 42(8):313-317. PubMed ID: 31206394
[TBL] [Abstract][Full Text] [Related]
55. Ipilimumab-associated halo-like inflammatory reactions around nevi during therapy for metastatic melanoma.
Alniemi DT; Fischer A; Greene LA; Pierson JC
Dermatol Online J; 2018 Jul; 24(7):. PubMed ID: 30261564
[TBL] [Abstract][Full Text] [Related]
56. Diplopia and Acute Vision Loss After Nivolumab Plus Ipilimumab Therapy.
Tambe A; Basnet A; Tambe V; Badrinath M; Mandru R
Am J Ther; 2020 Sep; 28(2):e246-e247. PubMed ID: 33687029
[No Abstract] [Full Text] [Related]
57. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
Hantel A; Gabster B; Cheng JX; Golomb H; Gajewski TF
J Immunother Cancer; 2018 Jul; 6(1):73. PubMed ID: 30012206
[TBL] [Abstract][Full Text] [Related]
58. [Vitiligo under checkpoint inhibitors].
Amini-Adle M; Dalle S
Ann Dermatol Venereol; 2018 Oct; 145(10):633-635. PubMed ID: 29866472
[No Abstract] [Full Text] [Related]
59. Uncommon esophagitis associated with nivolumab and ipilimumab therapy.
Inoue G; Utsumi T; Yoshizawa A
Dig Endosc; 2021 Mar; 33(3):467-468. PubMed ID: 33251627
[No Abstract] [Full Text] [Related]
60. Chronic inflammatory demyelinating polyradiculoneuropathy secondary to immune checkpoint inhibitors in melanoma patients.
Patel AS; Snook RJ; Sehdev A
Discov Med; 2019 Aug; 28(152):107-111. PubMed ID: 31926582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
